Supplementary Figure 1 from PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor–Treated Melanoma Patients

Supplementary Figure 1. Heat map of patients grouped based on baseline (PRE) PD-L1, change in (Δ) PD-L1 expression, Δ tumor infiltrating lymphocytes (TILs) and Δ PD-1+ lymphocytes from PRE to early during treatment (EDT).